Two registry studies comparing Impella (Abiomed Inc., Danvers, Massachusetts) with intra-aortic balloon pump (IABP) use over time showed increased adverse events, including death and bleeding, in association with Impella, according to findings presented Sunday at the American Heart Association Scientific Sessions 2019 in Philadelphia.